<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36740569</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2058-7384</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><PubDate><Year>2023</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>International journal of immunopathology and pharmacology</Title><ISOAbbreviation>Int J Immunopathol Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Crosstalk between miR-146a and pro-inflammatory cytokines in patients with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>3946320231154998</StartPage><MedlinePgn>3946320231154998</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">03946320231154998</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/03946320231154998</ELocationID><Abstract><AbstractText>microRNA-146a (miR-146a) plays an essential role in immune anomalies and organ injury of systemic lupus erythematosus (SLE) by regulating the disease's inflammation and complications. Here, we analyzed the expression of miR-146a in SLE and a panel of pro-inflammatory cytokines (IL-1, IL-6, IL-8, IL-17, and TNF-&#x3b1;). Association between all measured parameters and the disease's clinical manifestation and response to treatment was monitored. Our study populations were 113 SLE patients and 104 healthy volunteers. miR-146a expression in peripheral blood mononuclear cells (PBMCs) was measured by quantitative real-time PCR (RT-qPCR). The content of the plasma cytokines (IL-1&#x3b2;, IL-6, IL-8, IL-17, and TNF-&#x3b1;) was detected by enzyme-linked immunosorbent assay (ELISA). Compared with healthy controls, miR-146a expression was significantly increased (<i>p</i> &lt; 0.05) in lupus patients. The analysis of the receiver operator characteristic curve (ROC) of miR-146a showed 91% sensitivity and 70% specificity. IL-1&#x3b2;, IL-6, and IL-17 cytokines were significantly increased (<i>p</i> &lt; 0.001), while IL-8 and TNF-&#x3b1; were significantly decreased (<i>p</i> &lt; 0.001) in SLE patients against controls. The expression of miR-146a and TNF-&#x3b1; was upregulated considerably in SLE patients with severe disease activity. miR-146a expression was positively correlated with IL-6. Our results pointed to the elevation of miR-146a as a trade marker of SLE patients. Reduction of IL-8 and TNF-&#x3b1; in combination with an elevation of IL-1&#x3b2;, IL-6, and IL-17 might refer to miR-146a's dual effect in controlling inflammation in lupus. Although we shed some light on the role of miR-146a in SLE, further study is recommended to improve our results.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>El-Akhras</LastName><ForeName>Basima A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute, 392053Sadat City University, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talaat</LastName><ForeName>Roba M</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0000-0002-1176-2727</Identifier><AffiliationInfo><Affiliation>Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute, 392053Sadat City University, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Masry</LastName><ForeName>Samir A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute, 392053Sadat City University, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassyouni</LastName><ForeName>Iman H</ForeName><Initials>IH</Initials><AffiliationInfo><Affiliation>Rheumatology and Rehabilitation Department, Faculty of Medicine, 63527Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Sayed</LastName><ForeName>Ibrahim H</ForeName><Initials>IH</Initials><AffiliationInfo><Affiliation>Biochemistry Department, Faculty of Science, 289154Kafr El-Sheikh University, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Yasser Bm</ForeName><Initials>YB</Initials><AffiliationInfo><Affiliation>Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute, 392053Sadat City University, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Immunopathol Pharmacol</MedlineTA><NlmUniqueID>8911335</NlmUniqueID><ISSNLinking>0394-6320</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C542542">MIRN146 microRNA, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">miR-146a</Keyword><Keyword MajorTopicYN="N">pro-inflammatory cytokines</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>5</Day><Hour>22</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36740569</ArticleId><ArticleId IdType="pmc">PMC9903020</ArticleId><ArticleId IdType="doi">10.1177/03946320231154998</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Honarpisheh M, K&#xf6;hler P, von Rauchhaupt E, et al. (2018) The involvement of microRNAs in modulation of innate and adaptive immunity in systemic lupus erythematosus and lupus nephritis. Journal of Immunology Research 2018: 4126106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964414</ArticleId><ArticleId IdType="pubmed">29854836</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy D, Shaheen NH, Selim HM, et al. (2020) MicroRNA-126 and 146a as potential biomarkers in systemic lupus erythematosus patients with secondary antiphospholipid syndrome. The Egyptian Rheumatologist 42: 201&#x2013;206.</Citation></Reference><Reference><Citation>Hamam R, Ali AM, Alsaleh KA, et al. (2016) microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Scientific Reports 6: 25997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867432</ArticleId><ArticleId IdType="pubmed">27180809</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras J, Rao DS. (2012) MicroRNAs in inflammation and immune responses. Leukemia 26: 404&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">22182919</ArticleId></ArticleIdList></Reference><Reference><Citation>Taganov KD, Boldin MP, Chang KJ, et al. (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proceedings of the National Academy of Sciences of the United States of America 103: 12481&#x2013;12486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1567904</ArticleId><ArticleId IdType="pubmed">16885212</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldin MP, Taganov KD, Rao DS, et al. (2011) miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. The Journal of Experimental Medicine 208: 1189&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3173243</ArticleId><ArticleId IdType="pubmed">21555486</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonkoly E, Wei T, Janson PCJ, et al. (2007) MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One 2: e610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1905940</ArticleId><ArticleId IdType="pubmed">17622355</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayeldeen G, Nassar Y, Ahmed H, et al. (2018) Possible use of miRNAs-146a and -499 expression and their polymorphisms as diagnostic markers for rheumatoid arthritis. Molecular and Cellular Biochemistry 449: 145&#x2013;156. DOI: 10.1007/s11010-018-3351-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-018-3351-7</ArticleId><ArticleId IdType="pubmed">29700729</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakaria SS, Gaballah HH, El Saadany HM. (2016) Micro RNA-146a expression, NF-jB/P65 activity and serum pentosidine levels as potential biomarkers for disease severity in primary knee osteoarthritis patients. The Egyptian Rheumatologist 42: 201&#x2013;206.</Citation></Reference><Reference><Citation>Labib DA, Shaker OG, El Refai RM, et al. (2019) Association between miRNA-146a and polymorphisms of its target gene, IRAK1, regarding susceptibility to and clinical features of systemic lupus erythematous and multiple sclerosis. Laboratory Medicine 50: 34&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">30060033</ArticleId></ArticleIdList></Reference><Reference><Citation>Labib DA, Koptan D, Ghoniem S, et al. (2020) dysregulation of microRNA146a-5p expression in systemic lupus erythematosus females: diagnostic potential and association with ocular manifestations. The Egyptian Rheumatologist 42: 117&#x2013;121.</Citation></Reference><Reference><Citation>Tan G, Baby B, Zhou Y, et al. (2021) Emerging molecular markers towards potential diagnostic panels for lupus. Frontiers in Immunology 12: 808839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8792845</ArticleId><ArticleId IdType="pubmed">35095896</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Wang X, Choi IY, et al. (2017) miR-146a modulates autoreactive Th17 cell differentiation and regulates organ-specific autoimmunity. The Journal of Clinical Investigation 127: 3702&#x2013;3716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5617680</ArticleId><ArticleId IdType="pubmed">28872459</ArticleId></ArticleIdList></Reference><Reference><Citation>Radwan N, Hamza MT, Ghareeb I, et al. (2021) Serum interleukin-17 expression in a group of Egyptian patients with juvenile systemic lupus erythematosus. The Egyptian Journal of Pediatric Allergy and Immunology 19: 97&#x2013;103.</Citation></Reference><Reference><Citation>Tsai CY, Wu TH, Yu CL, et al. (2000) Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 85: 207&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867535</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahid MA, Satoh M, Chan EK. (2011) MicroRNA in TLR signaling and endotoxin tolerance. Cellular &amp; Molecular Immunology 8: 388&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3618661</ArticleId><ArticleId IdType="pubmed">21822296</ArticleId></ArticleIdList></Reference><Reference><Citation>Umare V, Pradhan V, Nadkar M, et al. (2014) Effect of proinflammatory cytokines (IL-6, TNF-&#x3b1;, and IL-1&#x3b2;) on clinical manifestations in Indian SLE patients. Mediators of Inflammation 2014: 385297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4273527</ArticleId><ArticleId IdType="pubmed">25548434</ArticleId></ArticleIdList></Reference><Reference><Citation>Talaat RM, Mohamed SF, Bassyouni IH, et al. (2015) Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine 72: 146&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">25647269</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Xue Z, Di L. (2017) Regulation of MiR-146a and TRAF6 in the diagnose of lupus nephritis. Medical Science Monitor 23: 2550&#x2013;2557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5455804</ArticleId><ArticleId IdType="pubmed">28549054</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao YM, Zhao CN, Liu LN, et al. (2018) Increased circulating interleukin-8 levels in systemic lupus erythematosus patients: a meta-analysis. Biomarkers in Medicine 12: 1291&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pubmed">30511585</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C, Zhao L, Wang K, et al. (2019) MicroRNA-146a inhibits NF-&#x3ba;B activation and pro-inflammatory cytokine production by regulating IRAK1 expression in THP-1 cells. Experimental and Therapeutic Medicine 18: 3078&#x2013;3084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6755493</ArticleId><ArticleId IdType="pubmed">31572547</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen HH, Fan Y, Wang YN, et al. (2020) Elevated circulating interleukin-17 levels in patients with systemic lupus erythematosus: a meta-analysis. Immunological Investigations 49: 662&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">31847623</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao M, Wang X, Zhang X, et al. (2015) Attenuation of cardiac dysfunction in polymicrobial sepsis by microRNA-146a is mediated via targeting of IRAK1 and TRAF6 expression. Journal of Immunology 195: 672&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4490963</ArticleId><ArticleId IdType="pubmed">26048146</ArticleId></ArticleIdList></Reference><Reference><Citation>Stypi&#x144;ska B, Paradowska-Gorycka A. (2015) Cytokines and MicroRNAs as candidate biomarkers for systemic lupus erythematosus. International Journal of Molecular Sciences 16: 24194&#x2013;24218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632746</ArticleId><ArticleId IdType="pubmed">26473848</ArticleId></ArticleIdList></Reference><Reference><Citation>Arag&#xf3;n CC, Taf&#xfa;r RA, Su&#xe1;rez-Avellaneda A, et al. (2020) Urinary biomarkers in lupus nephritis. Journal of Translational Autoimmunity 3: 100042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388339</ArticleId><ArticleId IdType="pubmed">32743523</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarc&#xf3;n GS, et al. (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism 64: 2677&#x2013;2686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombardier C, Gladman DD, Urowitz MB, et al. (1992) Derivation of the SLEDAI. a disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis and Rheumatism 35: 630&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">1599520</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca M, Bombardieri S. (2006) Assessing remission in systemic lupus erythematosus. Clinical and Experimental Rheumatology 24: 99&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">17083771</ArticleId></ArticleIdList></Reference><Reference><Citation>Abo ElAtta AS, Ali YBM, Bassyouni IH, et al. (2019) Upregulation of miR-221/222 expression in rheumatoid arthritis (RA) patients: correlation with disease activity. Clinical and Experimental Medicine 19: 47&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">30132091</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheita TA, Noor RA, Abualfadl E, et al. (2021) Adult systemic lupus erythematosus in Egypt: The nation-wide spectrum of 3661 patients and world-wide standpoint. Lupus 30(9): 1526&#x2013;1535. DOI: 10.1177/09612033211014253</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211014253</ArticleId><ArticleId IdType="pubmed">33951965</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Zheng Y, Liu S, et al. (2018) MiR-146a protects small intestine against ischemia/reperfusion injury by down-regulating TLR4/TRAF6/NF-&#x3ba;B pathway. Journal of Cellular Physiology 233: 2476&#x2013;2488.</Citation><ArticleIdList><ArticleId IdType="pubmed">28771774</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q, Yang Y, Zhao M, et al. (2015) Mycophenolic acid upregulates miR-142-3P/5P and miR-146a in lupus CD4+T cells. Lupus 24: 935&#x2013;942.</Citation><ArticleIdList><ArticleId IdType="pubmed">25661834</ArticleId></ArticleIdList></Reference><Reference><Citation>Shumnalieva R, Kachakova D, Shoumnalieva-Ivanova V, et al. (2018) Whole peripheral blood miR-146a and miR-155 expression levels in Systemic lupus erythematosus patients. Acta Reumatologica Portuguesa 43: 217&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">30414370</ArticleId></ArticleIdList></Reference><Reference><Citation>Zununi Vahed S, Nakhjavani M, Etemadi J, et al. (2018) Altered levels of immune-regulatory microRNAs in plasma samples of patients with lupus nephritis. BioImpacts 8: 177&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6128973</ArticleId><ArticleId IdType="pubmed">30211077</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Hernandez J, Forner MJ, Pinto C, et al. (2015) Increased urinary exosomal microRNAs in patients with systemic lupus erythematosus. PLoS One 10: e0138618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4577109</ArticleId><ArticleId IdType="pubmed">26390437</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y, Luo X, Cui H, et al. (2009) MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis and Rheumatism 60: 1065&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pubmed">19333922</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Tam LS, Li EKM, et al. (2010) Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus. The Journal of Rheumatology 37: 2516&#x2013;2522.</Citation><ArticleIdList><ArticleId IdType="pubmed">20952466</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo X, Yang W, Ye DQ, et al. (2011) A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS genetics 7: e1002128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128113</ArticleId><ArticleId IdType="pubmed">21738483</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashad DI, Abdelmagid MH, Elsherif SH. (2012) microRNA146a expression in lupus patients with and without renal complications. Journal of Clinical Laboratory Analysis 26: 35&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6807509</ArticleId><ArticleId IdType="pubmed">24833532</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahid S, Shahid W, Shaheen J, et al. (2021) Circulating miR-146a expression as a non-invasive predictive biomarker for acute lymphoblastic leukemia. Scientific Reports 11: 22783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8611079</ArticleId><ArticleId IdType="pubmed">34815474</ArticleId></ArticleIdList></Reference><Reference><Citation>Paquissi FC, Abensur H. (2021) The Th17/IL-17 axis and kidney diseases, with focus on lupus nephritis. Frontiers in Medicine 8: 654912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8446428</ArticleId><ArticleId IdType="pubmed">34540858</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez E, Guevara J, PAez A, et al. (2008) The altered expression of inflammation-related molecules and secretion of IL-6 and IL-8 by HUVEC from newborns with maternal inactive systemic lupus erythematosus is modified by estrogens. Lupus 17: 1086&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">19029276</ArticleId></ArticleIdList></Reference><Reference><Citation>Mende R, Vincent FB, Kandane-Rathnayake R, et al. (2018) Analysis of serum interleukin (IL)-1&#x3b2; and IL-18 in systemic lupus erythematosus. Frontiers in Immunology 9: 1250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5999794</ArticleId><ArticleId IdType="pubmed">29930551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J, Su S, You T, et al. (2020) Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythematosus: a meta-analysis. Clinics (Sao Paulo) 75: e1801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536892</ArticleId><ArticleId IdType="pubmed">33084768</ArticleId></ArticleIdList></Reference><Reference><Citation>Koizumi Y, Sakagami T, Nishiyama N, et al. (2017) Rituximab restores IFN--STAT1 function and ameliorates disseminated mycobacterium avium infection in a patient with anti-interferon- autoantibody. Journal of Clinical Immunology 37: 644&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">28779413</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetchotisakd P, Anunnatsiri S, Nanagara R, et al. (2018) Intravenous cyclophosphamide therapy for anti-IFN-gamma autoantibody-associated mycobacterium abscessus infection. Journal of Immunology Research 2018: 6473629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6330823</ArticleId><ArticleId IdType="pubmed">30687765</ArticleId></ArticleIdList></Reference><Reference><Citation>Howe HS, Leung BPL. (2019) Anti-cytokine autoantibodies in systemic lupus erythematosus. Cells 9: 72. DOI: 10.3390/cells9010072</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9010072</ArticleId><ArticleId IdType="pmc">PMC7016754</ArticleId><ArticleId IdType="pubmed">31892200</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu LJ, Yang X, Yu XQ. (2010) Anti-TNF-&#x3b1; therapies in systemic lupus erythematosus. Journal of Biomedicine &amp; Biotechnology 2010: 465898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2896679</ArticleId><ArticleId IdType="pubmed">20625488</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaumik D, Scott GK, Schokrpur S, et al. (2009) MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging (Albany N Y) 1: 402&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818025</ArticleId><ArticleId IdType="pubmed">20148189</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson ES, Werth VP. (2015) The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine 73: 326&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">25767072</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Jang W, Park HS, et al. (2020) Cytokine clusters as potential diagnostic markers of disease activity and renal involvement in systemic lupus erythematosus. The Journal of International Medical Research 48: 300060520926882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271280</ArticleId><ArticleId IdType="pubmed">32489126</ArticleId></ArticleIdList></Reference><Reference><Citation>Postal M, Appenzeller S. (2011) The role of tumor necrosis factor-alpha (TNF-&#x3b1;) in the pathogenesis of systemic lupus erythematosus. Cytokine 56: 537&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">21907587</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>